Skip to main content
Skip to main content
LNSR logo

LENSAR, Inc. (LNSR)

$6.24 $-0.16 (-2.50%) |Weak · 37
Signals are mixed — the Council read leans HOLD (49/100) while the AI fundamental score is 37/100 (grade D); the two lenses disagree, so weigh the breakdown below. Strongest signal: Ken Griffin bullish · Biggest watch-out: Seth Klarman bearish.
MCap: $75.53M| P/E Ratio: 2.3| Vol: 28.2K| Target: $10.00 (+60.3%)| 52-wk range: $5.06 – $13.47
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

LENSAR, Inc. (LNSR) trades at $6.24 with AI Score 37/100 (Grade D). LENSAR, Inc. specializes in femtosecond laser systems for cataract treatment and astigmatism management. Market cap: $75.53M, Sector: Healthcare.

Price live · AI analysis from May 9, 2026
LENSAR, Inc. specializes in femtosecond laser systems for cataract treatment and astigmatism management. Their technology aims to improve surgical outcomes through precision imaging and procedure planning.

LNSR stock analysis for 2026: Analysts have set a consensus price target of $10.00 for LENSAR, Inc., suggesting 60.3% upside from the current price of $6.24. The AI MoonshotScore is 37/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Council Score · Weighted Average of 3 Disciplines
HOLD 49/100 · C

LNSR: 4/7 perspectives are bullish. Dominant signal: Seth Klarman bearish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Ken Griffin
Bullish
Jim Simons
Neutral
Izzy Englander
Bullish
Seth Klarman
Bearish
Moon AI
Bullish
Council Score · 8 perspectives · See tabs for details →

LENSAR, Inc. (LNSR) Healthcare & Pipeline Overview

CEONicholas T. Curtis
Employees140
HeadquartersOrlando, FL, US
IPO Year2020

LENSAR, Inc. develops and markets femtosecond laser systems for cataract and astigmatism treatment, leveraging proprietary imaging and planning technologies. The company aims to enhance surgical precision and visual outcomes in the medical device sector, operating within the broader healthcare industry.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 9, 2026

What Is the Investment Thesis for LNSR?

LENSAR, Inc. presents a focused investment opportunity within the medical device sector, driven by its proprietary femtosecond laser technology for cataract and astigmatism treatment. With a market capitalization of $75.53M and a P/E ratio of 2.3, LENSAR shows potential for growth, supported by a strong profit margin of 50.9%. The company's growth catalysts include expanding its installed base of LENSAR Laser Systems and increasing utilization rates among existing customers. Key value drivers include the company's ability to innovate and develop new applications for its laser technology, as well as its potential to expand into new geographic markets. However, potential risks include competition from established players in the ophthalmic surgical device market and the need for ongoing investment in research and development to maintain its technological edge. The company's beta of 0.98 suggests moderate volatility relative to the market.

Based on FMP financials and quantitative analysis

LNSR Key Highlights

  • Market capitalization of $75.53M indicates the company's current valuation in the market.
  • P/E ratio of 2.3 suggests the stock may be undervalued compared to its earnings.
  • Profit margin of 50.9% demonstrates strong profitability and efficient operations.
  • Gross margin of 45.3% reflects the company's ability to control production costs and maintain pricing power.
  • Beta of 0.98 indicates the stock's volatility is similar to the overall market.

Who Are LNSR's Competitors?

LNSR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
ALC Alcon Inc. $68.47 -1.71% $33.39B 51
JNJ Johnson & Johnson $258.13 -1.87% $621.38B 90
BHC Bausch Health Companies Inc. $4.78 -2.45% $1.79B 50
DCTH Delcath Systems, Inc. $13.61 +3.11% $469.84M 73
PYNKF Perimeter Medical Imaging AI, Inc. $0.20 +3.40% $18.68M 73
SSII SS Innovations International, Inc. $3.76 -0.53% $752.49M 72
RSHUF Respiri Limited $0.06 +0.00% $91.52M 68
EW Edwards Lifesciences Corporation $95.44 +1.14% $54.96B 58

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LNSR's Key Strengths?

  • Proprietary femtosecond laser technology.
  • Strong profit margin of 50.9%.
  • Established presence in the ophthalmic surgical device market.
  • Advanced imaging and procedure planning capabilities.

What Are LNSR's Weaknesses?

  • Relatively small market capitalization of $75.53M.
  • Limited geographic reach compared to larger competitors.
  • Dependence on a single product line (LENSAR Laser System).
  • Requires ongoing investment in research and development.

What Could Drive LNSR Stock Higher?

  • Continued expansion of the installed base of LENSAR Laser Systems in ophthalmic clinics and hospitals.
  • Increasing utilization rates among existing customers through enhanced training and support programs.
  • Potential regulatory approvals for new applications of the LENSAR Laser System in additional ophthalmic procedures.
  • Strategic partnerships with key opinion leaders and influential surgeons to promote the adoption of LENSAR technology.
  • Ongoing research and development efforts to enhance the capabilities and features of the LENSAR Laser System.

What Are the Key Risks for LNSR?

  • Financial-distress signal — its Altman Z-Score of 0.91 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
  • Competition from established players in the ophthalmic surgical device market, such as Alcon, Johnson & Johnson Vision, and Bausch + Lomb.
  • Technological advancements by competitors that could render the LENSAR Laser System obsolete.
  • Regulatory changes and healthcare reforms that could impact the adoption and reimbursement of cataract surgery procedures.
  • Economic downturns that could affect healthcare spending and reduce demand for elective surgical procedures.
  • Dependence on a single product line (LENSAR Laser System) makes the company vulnerable to market shifts and technological disruptions.

What Are the Growth Opportunities for LNSR?

  • Expansion into international markets represents a significant growth opportunity for LENSAR. The global market for cataract surgery devices is expected to grow, driven by the increasing prevalence of cataracts in aging populations worldwide. By expanding its sales and marketing efforts into new geographic regions, LENSAR can tap into this growing demand and increase its revenue. The timeline for this expansion will depend on regulatory approvals and market entry strategies, but it represents a long-term growth driver for the company. Successfully entering new markets could significantly increase LENSAR's market share and revenue.
  • Increasing the utilization rate of existing LENSAR Laser Systems is another key growth opportunity. LENSAR can work with its existing customers to provide additional training and support, helping them to perform more procedures using the LENSAR system. This would not only increase revenue from single-use procedure packs but also strengthen customer relationships and loyalty. The timeline for this growth opportunity is relatively short-term, as it can be achieved through targeted sales and marketing efforts. By focusing on customer satisfaction and providing ongoing support, LENSAR can drive increased utilization and revenue growth.
  • Developing new applications for the LENSAR Laser System beyond cataract surgery and astigmatism management could open up new markets and revenue streams. For example, LENSAR could explore the use of its laser technology for other ophthalmic procedures, such as corneal refractive surgery or glaucoma treatment. This would require further research and development, but it could significantly expand the company's addressable market. The timeline for this growth opportunity is longer-term, as it will depend on the success of research and development efforts and regulatory approvals. However, it represents a significant potential growth driver for the company.
  • Strategic partnerships with ophthalmic surgeons and clinics can help LENSAR to increase its market reach and brand awareness. By collaborating with key opinion leaders and influential surgeons, LENSAR can gain valuable insights into market trends and customer needs. These partnerships can also help to promote the LENSAR Laser System and increase its adoption among surgeons. The timeline for this growth opportunity is ongoing, as LENSAR can continuously seek out new partnerships and collaborations. By building strong relationships with key stakeholders in the ophthalmic community, LENSAR can strengthen its competitive position and drive growth.
  • Investing in research and development to enhance the capabilities of the LENSAR Laser System is essential for maintaining a competitive edge. By continuously innovating and developing new features and applications for its technology, LENSAR can attract new customers and retain existing ones. This includes improving the precision and accuracy of the laser system, as well as developing new software and imaging capabilities. The timeline for this growth opportunity is ongoing, as LENSAR must continuously invest in research and development to stay ahead of the competition. By maintaining a focus on innovation, LENSAR can drive long-term growth and create value for its shareholders.

What Opportunities Does LNSR Have?

  • Expansion into international markets.
  • Increasing utilization rate of existing LENSAR Laser Systems.
  • Developing new applications for the LENSAR Laser System.
  • Strategic partnerships with ophthalmic surgeons and clinics.

What Threats Does LNSR Face?

  • Competition from established players in the ophthalmic surgical device market.
  • Technological advancements by competitors.
  • Regulatory changes and healthcare reforms.
  • Economic downturns affecting healthcare spending.

What Are LNSR's Competitive Advantages?

  • Proprietary femtosecond laser technology with advanced imaging and planning capabilities.
  • Established installed base of LENSAR Laser Systems in ophthalmic clinics and hospitals.
  • Strong relationships with ophthalmic surgeons and key opinion leaders.
  • Ongoing investment in research and development to maintain technological edge.

What Does LNSR Do?

LENSAR, Inc., established in 2004 and headquartered in Orlando, Florida, is a commercial-stage medical device company focused on advancing cataract surgery and astigmatism management through innovative laser technology. The company designs, develops, and markets the LENSAR Laser System, a femtosecond laser platform that incorporates proprietary technologies aimed at improving surgical precision, efficiency, and patient outcomes. The LENSAR system provides surgeons with advanced imaging, procedure planning, and design capabilities to assist in cataract removal and the correction of pre-existing or surgically induced corneal astigmatism. The LENSAR Laser System's key features include its advanced 3D modeling and precise laser delivery, which allow surgeons to create customized treatment plans tailored to each patient's unique anatomy. This technology aims to enhance the accuracy and reproducibility of cataract surgery, potentially leading to better visual outcomes and reduced complications. LENSAR's focus on innovation and technological advancement positions it as a player in the ophthalmic surgical device market, serving ophthalmologists and surgeons seeking to improve their surgical techniques and patient care. LENSAR's business model involves the sale and service of its LENSAR Laser Systems, as well as the sale of single-use procedure packs. The company's revenue is derived from these sources, as well as from service contracts and training programs for surgeons and staff. LENSAR's commitment to ongoing research and development ensures that its technology remains at the forefront of the ophthalmic surgical field.

What Products and Services Does LNSR Offer?

  • Designs and develops femtosecond laser systems for cataract surgery.
  • Markets the LENSAR Laser System to ophthalmic surgeons and clinics.
  • Provides advanced imaging and procedure planning capabilities.
  • Offers solutions for managing pre-existing or surgically induced astigmatism.
  • Enhances surgical precision and reproducibility in cataract treatment.
  • Provides training and support to surgeons using the LENSAR system.
  • Sells single-use procedure packs for use with the LENSAR Laser System.

How Does LNSR Make Money?

  • Sales of LENSAR Laser Systems to ophthalmic surgeons and clinics.
  • Recurring revenue from the sale of single-use procedure packs.
  • Service contracts and maintenance agreements for the LENSAR Laser Systems.
  • Training programs and support services for surgeons and staff.

What Industry Does LNSR Operate In?

LENSAR, Inc. operates within the medical device industry, specifically focusing on ophthalmic surgical devices. The market for cataract surgery devices is driven by the aging global population and the increasing prevalence of cataracts. The competitive landscape includes established players such as Alcon, Johnson & Johnson Vision, and Bausch + Lomb, as well as other smaller companies offering femtosecond laser systems. LENSAR differentiates itself through its proprietary technology and focus on precision and customization in cataract and astigmatism treatment. The industry is characterized by ongoing innovation and technological advancements, with companies constantly seeking to improve surgical outcomes and patient satisfaction.

Who Are LNSR's Key Customers?

  • Ophthalmic surgeons specializing in cataract surgery.
  • Ophthalmology clinics and hospitals offering cataract treatment.
  • Patients seeking advanced cataract surgery options.
  • Healthcare providers focused on improving surgical outcomes and patient satisfaction.
AI Confidence: 72% Updated: May 9, 2026

P/E 2.3Key Financial Metrics

Return on assets is 44.4%, showing how much profit it generates from its asset base. LNSR trades at a trailing price-to-earnings ratio of 2.35, below the Healthcare sector average of ~23x. Its free cash flow yield is -17.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.38 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 42.0%, the inverse of the P/E and a quick read on earnings relative to price.

LENSAR, Inc. (LNSR) Valuation Context

Valued at $75.53M, LNSR is classified as a micro-cap stock. Relative to its peer group, LNSR's quantitative score of 37/100 is below the peer average of 67/100.

Company Profile

LENSAR, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Orlando, US. The company is led by CEO Nicholas T. Curtis. LNSR has traded publicly since 2020.

F-Score 3/9Financial Health

LENSAR, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.91 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project LENSAR, Inc. revenue of about $60.6M for fiscal 2026, with EPS near $0.79.

LNSR Financials

Fundamental Snapshot

Revenue Growth (FY)
+9.2%
Net Income Growth (FY)
-9.2%
EPS Growth (FY)
-5.1%
P/E (TTM)
2.4
Current Ratio
2.4
EV/EBITDA (TTM)
1.8

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Recent insider buying suggests confidence in LENSAR's future, signaling that executives believe in the company's growth potential.
  • Community sentiment has shifted positively, with discussions highlighting innovative developments in their laser technology.
  • Analysts are noting an uptick in demand for LENSAR's products, reflecting a growing market for advanced eye surgery solutions.
  • Positive news coverage has emphasized the company's strategic partnerships, which may enhance their market reach and operational capabilities.

Bear Case

  • Some investors express concerns about the competitive landscape, as new entrants in the medical technology space could pressure margins.
  • Recent discussions have highlighted potential regulatory challenges that could impact product approvals and market entry.
  • There are lingering worries about the overall economic climate affecting healthcare spending, which could dampen growth projections for LENSAR.
  • Community sentiment shows some skepticism about the company's ability to scale operations effectively amidst increasing competition.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

LNSR Latest News

LNSR Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LNSR.

Price Targets

Consensus target: $10.00

LNSR MoonshotScore

37/100

What does this score mean?

The MoonshotScore rates LNSR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Nicholas T. Curtis

CEO

Nicholas T. Curtis serves as the Chief Executive Officer of LENSAR, Inc., managing a team of 140 employees. His professional background includes extensive experience in the medical device industry, with a focus on strategic leadership and commercial development. Prior to joining LENSAR, Curtis held leadership positions at various medical technology companies, where he was responsible for driving revenue growth, expanding market share, and launching new products. His expertise spans across sales, marketing, and product development, making him well-suited to lead LENSAR in its mission to advance cataract surgery and astigmatism management.

Track Record: Under Nicholas T. Curtis's leadership, LENSAR, Inc. has focused on expanding its market presence and driving adoption of its LENSAR Laser System. Key achievements include strengthening relationships with ophthalmic surgeons and clinics, increasing the utilization rate of existing LENSAR systems, and investing in research and development to enhance the capabilities of the technology. Curtis has also overseen the implementation of strategic initiatives aimed at improving operational efficiency and driving revenue growth.

What Investors Ask About LENSAR, Inc. (LNSR) — Healthcare

What does LENSAR, Inc. do?

LENSAR, Inc. is a commercial-stage medical device company that designs, develops, and markets a femtosecond laser system for cataract treatment and astigmatism management. Their core product, the LENSAR Laser System, incorporates proprietary technologies aimed at improving surgical precision, efficiency, and patient outcomes. The system provides surgeons with advanced imaging, procedure planning, and design capabilities to assist in cataract removal and the correction of corneal astigmatism. LENSAR's business model revolves around the sale and service of its laser systems and related consumables, targeting ophthalmic surgeons and clinics.

What do analysts say about LNSR stock?

Analyst coverage of LNSR stock is limited, given its small market capitalization. However, key valuation metrics such as the P/E ratio of 2.3 and a profit margin of 50.9% suggest potential value. Growth considerations include the company's ability to expand its installed base of LENSAR Laser Systems, increase utilization rates among existing customers, and develop new applications for its technology. Investors should carefully consider the company's competitive position, financial performance, and growth prospects before making any investment decisions. Analyst consensus is not readily available due to limited coverage.

What are the main risks for LNSR?

LENSAR faces several key risks, including competition from larger, more established players in the ophthalmic surgical device market. Technological advancements by competitors could also render the LENSAR Laser System obsolete. Regulatory changes and healthcare reforms could impact the adoption and reimbursement of cataract surgery procedures. Economic downturns could affect healthcare spending and reduce demand for elective surgical procedures. Additionally, the company's dependence on a single product line makes it vulnerable to market shifts and technological disruptions. Investors should carefully consider these risks before investing in LNSR.

What are the key factors to evaluate for LNSR?

LENSAR, Inc. (LNSR) holds an AI score of 37/100 (low). P/E: 2.3x vs the S&P 500's ~20-25x. Analysts target $10.00 (+60%). Not financial advice.

How frequently does LNSR data refresh on this page?

LNSR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven LNSR's recent stock price performance?

LENSAR, Inc. (LNSR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary femtosecond laser technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LNSR overvalued or undervalued right now?

LENSAR, Inc. (LNSR) trades at 2.3x earnings. Analysts target $10.00 (+60%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying LNSR?

Before investing in LENSAR, Inc. (LNSR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
  • Analyst opinions and ratings may vary.
Data Sources

Popular Stocks